Analysts Offer Predictions for ENSC FY2027 Earnings

Ensysce Biosciences, Inc. (NASDAQ:ENSC) – Analysts at Zacks Research issued their FY2027 EPS estimates for Ensysce Biosciences in a research note issued to investors on Tuesday, March 31st. Zacks Research analyst B. Sorensen anticipates that the company will post earnings of ($0.20) per share for the year. The consensus estimate for Ensysce Biosciences’ current full-year earnings is ($8.33) per share.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Ensysce Biosciences in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Ensysce Biosciences has a consensus rating of “Sell”.

Ensysce Biosciences Trading Up 4.8%

NASDAQ:ENSC opened at $0.54 on Wednesday. Ensysce Biosciences has a 12 month low of $0.31 and a 12 month high of $4.85. The stock has a 50 day moving average of $0.55 and a two-hundred day moving average of $1.33. The firm has a market cap of $1.95 million, a P/E ratio of -0.13 and a beta of 1.14.

Ensysce Biosciences (NASDAQ:ENSC) last released its quarterly earnings results on Monday, March 30th. The company reported ($0.75) earnings per share for the quarter, topping the consensus estimate of ($1.26) by $0.51. The firm had revenue of $1.88 million during the quarter, compared to the consensus estimate of $0.50 million. Ensysce Biosciences had a negative net margin of 200.87% and a negative return on equity of 458.65%.

Institutional Investors Weigh In On Ensysce Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of ENSC. Adage Capital Partners GP L.L.C. raised its stake in Ensysce Biosciences by 100.4% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 149,711 shares of the company’s stock worth $138,000 after purchasing an additional 75,000 shares during the period. DRW Securities LLC grew its stake in shares of Ensysce Biosciences by 42.4% in the 4th quarter. DRW Securities LLC now owns 98,481 shares of the company’s stock valued at $91,000 after buying an additional 29,336 shares during the period. Citadel Advisors LLC purchased a new stake in shares of Ensysce Biosciences in the 3rd quarter valued at approximately $34,000. Virtu Financial LLC acquired a new stake in shares of Ensysce Biosciences during the 3rd quarter worth approximately $34,000. Finally, TRU Independence Asset Management 2 LLC acquired a new stake in shares of Ensysce Biosciences during the 3rd quarter worth approximately $25,000. 5.63% of the stock is currently owned by institutional investors and hedge funds.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.